Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity

Area of Science:

• Pharmacology
• Nephrology
• Epigenetics

Background:

• Cisplatin is a vital chemotherapy drug but causes significant kidney damage (nephrotoxicity).
• Epigenetic modifications, specifically histone acetylation changes, are implicated in cisplatin nephrotoxicity.
• Bromodomain and extraterminal (BET) proteins are key regulators of histone acetylation.

Purpose of the Study:

• To investigate the renoprotective potential of JQ1, a small molecule inhibitor of BET proteins, against cisplatin-induced nephrotoxicity.
• To elucidate the underlying molecular mechanisms of JQ1's protective effects.

Main Methods:

• Administration of JQ1 to mice undergoing cisplatin treatment.
• Assessment of kidney function, histopathology, and renal tubular apoptosis.
• Analysis of molecular pathways including DNA damage response (p53, Chk2), MAP kinases, and oxidative/nitrosative stress markers.

Main Results:

• JQ1 significantly ameliorated cisplatin-induced nephrotoxicity in mice, improving kidney function and reducing tubular apoptosis.
• JQ1 partially prevented body weight loss and inhibited apoptosis in renal proximal tubular cells.
• Mechanistically, JQ1 suppressed cisplatin-induced p53/Chk2 activation, attenuated MAP kinase signaling, and modulated antioxidant/nitrosative stress pathways.

Conclusions:

• JQ1 demonstrates significant renoprotective effects against cisplatin-induced nephrotoxicity in a preclinical model.
• The protective mechanisms involve the suppression of DNA damage response, p53, MAP kinases, and oxidative/nitrosative stress.
• JQ1's targeted action on kidney cells, without affecting cancer cell apoptosis, highlights its potential as a specific renoprotective agent.